Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.79 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | HTR1B | P28222 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11006154 | 0.90 | PARP1 (0.70) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL11004751 | 0.90 | PARP1 (0.70) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL21207261 | 0.89 | PARP1 (0.74) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL532134 | 0.89 | PARP1 (1.00) | PARP1NR3C2MMP12PKMDRD2 | |
| SCHEMBL12844300 | 0.86 | PARP1 (0.78) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL31033201 | 0.86 | PARP1 (0.78) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL11002313 | 0.85 | PARP1 (0.77) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL4257167 | 0.85 | PARP1 (0.70) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL4173613 | 0.85 | PARP1 (0.63) | PARP1NR3C2MMP12DRD2DRD4 | |
| SCHEMBL9244955 | 0.83 | PARP1 (0.65) | PARP1NR3C2MMP12DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | claimed |
| US-12545653-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| CN-114409680-B | PPAR agonists and uses thereof | 上海怡立舍生物技术有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| CN-114409680-A | PPAR agonist and application thereof | 上海怡立舍生物技术有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-108250058-B | PPAR agonists and their use in the treatment of Alzheimer's disease and other diseases | 上海怡立舍生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
| CN-108250058-A | PPAR agonists and their use in the treatment of Alzheimer's disease and other diseases | 上海怡立舍生物技术有限公司 | 2018-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545653-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARD, PPARG | PARP1 2679/4885NR3C2 236/4885MMP12 2439/4885 |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARG, PPARD | PARP1 1957/4885NR3C2 711/4885MMP12 905/4885 |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | PARP1 1957/4885NR3C2 711/4885MMP12 905/4885 |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | PARP1 1957/4885NR3C2 711/4885MMP12 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.